A noncoding regulatory RNA Gm31932 induces cell cycle arrest and differentiation in melanoma via the miR-344d-3-5p/Prc1 (and Nuf2) axis

Wang, Dan; Chen, Jianfei; Li, Bohan; Jiang, Qingling; Liu, Ling; Xia, Ziyi; Zheng, Qi; Li, Minjing; Li, Defang

doi:10.1038/s41419-022-04736-6

Cited by 7 publications

(5 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NUF2 is an oncogene that reported in clear cell renal cell carcinoma 30 , melanoma 31 , hepatocellular carcinoma 32 , and breast cancer 33 . More importantly, in a phase I clinical trial, NUF2 peptide vaccination has been used to treat castration resistant prostate cancer (CRPC), and achieved encouraging results 34 .…”

Section: Discussionmentioning

confidence: 99%

NUF2 Drives Cholangiocarcinoma Progression and Migration via Inhibiting Autophagic Degradation of TFR1

Shan¹,

Jiang²,

Chang³

et al. 2023

Int. J. Biol. Sci.

View full text Add to dashboard Cite

Cholangiocarcinoma (CCA) is the second most common primary hepatic malignancy and associated with poor prognosis. Lack of therapeutic methods for CCA and insensitivity of targeted therapy and immunotherapy make its treatment challenging. NUF2, a component of Ndc80 kinetochore complex, is implicated in the initiation and development of multiple cancers. However, the role and mechanism of NUF2 in CCA is still unclear. In this research, we investigated the biological processes and underlying mechanisms of NUF2 in CCA. We discovered that the expression of NUF2 was upregulated in CCA and negatively correlated with prognosis. Changes in NUF2 levels had an impact on cell proliferation and migration. Moreover, NUF2 functioned as an oncogene to promote the progression of CCA through p38/MAPK signaling by inhibiting p62 binding of TFR1 and affecting its autophagic degradation. In addition, TFR1 promoted CCA progression and Kaplan-Meier analyses uncovered patients with high expression of TFR1 was associated with the poor survival. In conclusion, our study demonstrated that NUF2 promoted CCA progression by regulating TFR1 protein degradation, and the NUF2/TFR1/MAPK axis could be an excellent therapeutic target for CCA.

show abstract

Section: Discussionmentioning

confidence: 99%

NUF2 Drives Cholangiocarcinoma Progression and Migration via Inhibiting Autophagic Degradation of TFR1

Shan¹,

Jiang²,

Chang³

et al. 2023

Int. J. Biol. Sci.

View full text Add to dashboard Cite

show abstract

“…Additionally, the expression of lncRNA-UCA1 was upregulated in melanoma tissues compared to normal tissues, while the downregulation of UCA1 was controlled by direct binding with miR-507, resulting in cell proliferation, invasion, migration, metastasis and cell cycle arrest inhibition ( 67 ). Moreover, integrative transcriptome analysis demonstrated that lncRNA-Gm31932 has definite effects on cell cycle arrest and melanoma differentiation through the miR-344d-3-5p/Prc1 (and Nuf2) axis ( 68 ). LncRNA-HnRNPK (heterogeneous nuclear ribonucleoprotein K) acts as a ceRNA for miR-147a and regulates LINC00263, thus accelerating malignant capabilities by targeting CAPN2 ( 84 ).…”

Section: Lncrnas As Regulators In Melanomamentioning

confidence: 99%

The role of lncRNAs in the tumor microenvironment and immunotherapy of melanoma

Zhou

Cen

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Melanoma is one of the most lethal tumors with highly aggressive and metastatic properties. Although immunotherapy and targeted therapy have certain therapeutic effects in melanoma, a significant proportion of patients still have drug resistance after treatment. Recent studies have shown that long noncoding RNAs (lncRNAs) are widely recognized as regulatory factors in cancer. They can regulate numerous cellular processes, including cell proliferation, metastasis, epithelial-mesenchymal transition (EMT) progression and the immune microenvironment. The role of lncRNAs in malignant tumors has received much attention, whereas the relationship between lncRNAs and melanoma requires further investigation. Our review summarizes tumor suppressive and oncogenic lncRNAs closely related to the occurrence and development of melanoma. We summarize the role of lncRNAs in the immune microenvironment, immunotherapy and targeted therapy to provide new targets and therapeutic methods for clinical treatment.

show abstract

“…Multiple studies have shown that lncRNAs are involved in cancer. lncRNA-Gm31932 uses the miR-344d-3-5p/Prc1 axis, for example, to induce cell cycle arrest and differentiation in melanoma ( 10 ). LncRNA TINCR suppresses melanoma cell proliferation and invasion by regulating the miR-424-5p/LATS1 axis, and it also upregulates apoptosis ( 11 ).…”

Section: Introductionmentioning

confidence: 99%

Machine learning-based signature of necrosis-associated lncRNAs for prognostic and immunotherapy response prediction in cutaneous melanoma and tumor immune landscape characterization

et al. 2023

View full text Add to dashboard Cite

BackgroundCutaneous melanoma (CM) is one of the malignant tumors with a relative high lethality. Necroptosis is a novel programmed cell death that participates in anti-tumor immunity and tumor prognosis. Necroptosis has been found to play an important role in tumors like CM. However, the necroptosis-associated lncRNAs’ potential prognostic value in CM has not been identified.MethodsThe RNA sequencing data collected from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression Project (GTEx) was utilized to identify differentially expressed genes in CM. By using the univariate Cox regression analysis and machine learning LASSO algorithm, a prognostic risk model had been built depending on 5 necroptosis-associated lncRNAs and was verified by internal validation. The performance of this prognostic model was assessed by the receiver operating characteristic curves. A nomogram was constructed and verified by calibration. Furthermore, we also performed sub-group K-M analysis to explore the 5 lncRNAs’ expression in different clinical stages. Function enrichment had been analyzed by GSEA and ssGSEA. In addition, qRT-PCR was performed to verify the five lncRNAs’ expression level in CM cell line (A2058 and A375) and normal keratinocyte cell line (HaCaT).ResultsWe constructed a prognostic model based on five necroptosis-associated lncRNAs (AC245041.1, LINC00665, AC018553.1, LINC01871, and AC107464.3) and divided patients into high-risk group and low-risk group depending on risk scores. A predictive nomogram had been built to be a prognostic indicator to clinical factors. Functional enrichment analysis showed that immune functions had more relationship and immune checkpoints were more activated in low-risk group than that in high-risk group. Thus, the low-risk group would have a more sensitive response to immunotherapy.ConclusionThis risk score signature could be used to divide CM patients into low- and high-risk groups, and facilitate treatment strategy decision making that immunotherapy is more suitable for those in low-risk group, providing a new sight for CM prognostic evaluation.

show abstract

A noncoding regulatory RNA Gm31932 induces cell cycle arrest and differentiation in melanoma via the miR-344d-3-5p/Prc1 (and Nuf2) axis

Cited by 7 publications

References 37 publications

NUF2 Drives Cholangiocarcinoma Progression and Migration via Inhibiting Autophagic Degradation of TFR1

NUF2 Drives Cholangiocarcinoma Progression and Migration via Inhibiting Autophagic Degradation of TFR1

The role of lncRNAs in the tumor microenvironment and immunotherapy of melanoma

Machine learning-based signature of necrosis-associated lncRNAs for prognostic and immunotherapy response prediction in cutaneous melanoma and tumor immune landscape characterization

Contact Info

Product

Resources

About